Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.
Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.
Requires every individual or group health insurance contract, plan, or policy to provide coverage for at least one type of buprenorphine for each form of administration.
Provides an insurer would not impose prior authorization requirements for any service ordered by an in-network primary care provider.
Provides an insurer would not impose prior authorization requirements for any service ordered by an in-network primary care provider.
Provides an insurer would not impose prior authorization requirements for any service ordered by an in-network primary care provider.
Requires a report to be produced that focuses on prescription drug prior authorizations by January 1, 2026.
Requires a report to be produced that focuses on prescription drug prior authorizations by January 1, 2026.
Requires certified athletic trainers to be trained in the administration of epinephrine auto-injectors (epi-pens) and would require such professionals to be equipped with the medication while performing professional activities.
Requires certified athletic trainers to be trained in the administration of epinephrine auto-injectors (epi-pens) and would require such professionals to be equipped with the medication while performing professional activities.